GCG and kidney disorder: This analysis provides the first clinical support for the hypothesis that combinatorial use of GLP-1 RA and SGLT2i therapies may provide additional benefit on adjudicated cardiovascular outcomes, mortality, and renal disease progression, compared with GLP-1 RA without SGLT2i, and to standard of care with neither GLP-1 RA nor SGLT2i (Table 2).